Ind-Swift Labs.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE915B01019
NSEID: INDSWFTLAB
BSEID: 532305

INR

95.90

2.72 (2.92%)

BSENSE

Dec 05

BSE+NSE Vol: 1.33 lacs

{
  "main_header": {
    "sid": 393806,
    "name": "Ind-Swift Labs.",
    "stock_name": "Ind-Swift Labs.",
    "full_name": "Ind-Swift Laboratories Ltd",
    "name_url": "stocks-analysis/ind-swift-labs",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "95.90",
    "chg": 2.72,
    "chgp": "2.92%",
    "dir": 1,
    "prev_price": "93.18",
    "mcapval": "754.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532305,
    "symbol": "INDSWFTLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE915B01019",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.33 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ind-swift-labs-393806-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ind-Swift Labs. Sees Revision in Market Evaluation Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-labs-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3738020",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IndSwiftLabs_mojoScore_3738020.png",
        "date": "2025-12-01 10:09:27",
        "description": "Ind-Swift Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment highlights the evolving challenges the company faces amid a complex operating environment and fluctuating market sentiment."
      },
      {
        "title": "Why is Ind-Swift Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ind-swift-labs-fallingrising-3729819",
        "imagepath": "",
        "date": "2025-11-26 01:02:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Comparison</strong></p>\n<p>Ind-Swift Laboratories has experienced a consistent decline over recent trading sessions, with the stock falling for two consecutive days and registering a cumulative loss of 6.5% during this period. The intraday low touched ₹93.5, marking a 2.35% drop from previous levels. This underperformance is further highlighted by the stock’s returns relative to the broader market indices. Over the past week, the stock declined by 2.84%, significantly lagging behind the Sensex’s marginal dip of 0.10%. The one-month performance is even more stark, with Ind-Swift Labs falling 7.78% while the Sensex gained 0.45%. Year-to-date figures reveal a 14.18% loss for the stock, contrasting sharply with the Sensex’s 8.25% gain.</p>\n<p>Technical indicat..."
      },
      {
        "title": "Ind-Swift Laboratories Q2 FY26: Recovery Momentum Stalls Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/ind-swift-laboratories-q2-fy26-recovery-momentum-stalls-amid-margin-pressures-3718811",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndSwiftLaborat_quaterlyResult_3718811.png",
        "date": "2025-11-18 16:41:33",
        "description": "Ind-Swift Laboratories Ltd., the Chandigarh-based active pharmaceutical ingredient (API) manufacturer, reported a consolidated net profit of ₹7.99 crores for Q2 FY26, marking an impressive 1848.78% year-on-year growth from ₹0.41 crores in Q2 FY25. However, the quarter-on-quarter picture reveals concerning trends, with net profit declining 8.89% from ₹8.77 crores in Q1 FY26. The micro-cap company, with a market capitalisation of ₹814.00 crores, has seen its stock price decline 2.91% to ₹96.90 as investors digest the mixed quarterly performance."
      },
      {
        "title": "Ind-Swift Laboratories Faces Mixed Technical Trends Amid Recent Stock Evaluation Changes",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-technical-trend-shifts-from-mildly-bullish-to-mildly-bearish-amid-stock-decline-3710124",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndSwiftLaborat_technicaldot_3710124.png",
        "date": "2025-11-18 08:07:16",
        "description": "Ind-Swift Laboratories, a microcap in the Pharmaceuticals and Biotechnology sector, has experienced a stock price decline amid mixed technical indicators. Recent performance shows a notable drop compared to the Sensex, with year-to-date losses contrasting with long-term gains, emphasizing the importance of monitoring market conditions."
      },
      {
        "title": "Ind-Swift Laboratories Shows Stabilization Amidst Recent Financial Trend Adjustments",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-financial-trend-improves-from-negative-to-flat-amid-stabilization-3709579",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndSwiftLaborat_fintrenddot_3709579.png",
        "date": "2025-11-18 08:00:18",
        "description": "Ind-Swift Laboratories has experienced a flat financial performance for the quarter ending September 2025, with recent evaluations indicating stabilization in its metrics. The stock has shown volatility in trading, and while it has underperformed against the Sensex over the past year, it has outperformed over longer time frames."
      },
      {
        "title": "How has been the historical performance of Ind-Swift Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-ind-swift-labs-3708734",
        "imagepath": "",
        "date": "2025-11-17 23:03:16",
        "description": "Answer:\nThe historical performance of Ind-Swift Labs shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nInd-Swift Labs experienced a notable decline in net sales from INR 1,709.15 crore in March 2024 to INR 561.71 crore in March 2025, following a peak of INR 1,207.31 crore in March 2023. The total operating income mirrored this trend, dropping to INR 561.71 crore in March 2025 from INR 1,709.15 crore in the previous year. The company's operating profit (PBDIT) also fell sharply, resulting in a loss of INR 19.39 crore in March 2025, compared to a profit of INR 303.06 crore in March 2024. Despite these challenges, profit before tax remained positive at INR 257.80 crore in March 2025, although it decreased from INR 598.22 crore in March 2024. The profit after tax for March 2025 was INR 250.53 crore, down from INR 539.24 crore the previous year. On the balance sheet, total liabi..."
      },
      {
        "title": "Why is Ind-Swift Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ind-swift-labs-fallingrising-3708325",
        "imagepath": "",
        "date": "2025-11-17 22:20:08",
        "description": "As of 17-Nov, Ind-Swift Laboratories Ltd's stock price is currently at Rs 99.40, reflecting a decrease of Rs 4.5 or 4.33%. The stock has underperformed its sector by 4.61% today and has experienced a trend reversal after two consecutive days of gains. It reached an intraday low of Rs 99.1, indicating a significant drop of 4.62%. Additionally, the stock's performance over the past week shows a decline of 4.42%, and it has underperformed the benchmark Sensex, which has gained 1.69% during the same period. The delivery volume has also decreased by 14.86% compared to the five-day average, suggesting a decline in investor participation.\n\nBroader Market Context: In the context of the broader market, Ind-Swift Laboratories Ltd's year-to-date performance shows a decline of 9.39%, while the Sensex has risen by 8.72% during the same timeframe. This stark contrast highlights the stock's struggles compared to the overa..."
      },
      {
        "title": "Is Ind-Swift Labs. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ind-swift-labs-technically-bullish-or-bearish-3705751",
        "imagepath": "",
        "date": "2025-11-17 08:05:52",
        "description": "As of 14 November 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum. However, the weekly and monthly MACD and KST readings are mildly bearish, which suggests some caution. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish on the monthly. Dow Theory indicates a mildly bullish stance on both weekly and monthly timeframes. Overall, the mixed signals from different indicators suggest a cautious bullish outlook...."
      },
      {
        "title": "Ind-Swift Laboratories Shows Mixed Technical Trends Amid Market Fluctuations",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-stock-price-increase-3706242",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndSwiftLaborat_technicaldot_3706242.png",
        "date": "2025-11-17 08:00:58",
        "description": "Ind-Swift Laboratories, a microcap in the Pharmaceuticals and Biotechnology sector, has seen its stock price rise slightly. The company has experienced fluctuations over the past year, with notable returns compared to the Sensex. Its performance over three years has significantly outpaced the index, indicating resilience in a competitive market."
      }
    ],
    "total": 145,
    "sid": "393806",
    "stock_news_url": "https://www.marketsmojo.com/news/ind-swift-laboratories-393806"
  },
  "announcements": [
    {
      "details": "Ind-Swift Laboratories Limited has informed the Exchange regarding 'Prior Intimation under Regulation 50 (1) and 60 (2) of SEBI (Listing Obligations and Disclosure requirements), Regulations, 2015 of Record Date and redemption/Payment of Interest Date'.",
      "source": "NSE",
      "caption": "Ind-Swift Laboratories Limited - Updates",
      "datetime": "09-Dec-2019"
    },
    {
      "details": " <table><tr><td>Ind-Swift Laboratories Limited has informed the Exchange regarding 'Prior Intimation under Regulations 50(1) and 60(2) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 of Record date and payment of Interest Date'. </td></tr></table>",
      "source": "NSE",
      "caption": "Updates",
      "datetime": "16-Sep-2019"
    },
    {
      "details": " <table><tr><td>Ind-Swift Laboratories Limited has informed the Exchange regarding 'Intimation regarding Publication of Notice of 24th AnnualGeneral Meeting of the Company in the Newspaper'. </td></tr></table>",
      "source": "NSE",
      "caption": "Updates",
      "datetime": "09-Sep-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Ind-Swift Laboratories Ltd has declared <strong>10%</strong> dividend, ex-date: 20 Sep 11",
          "dt": "2011-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ind-Swift Labs. Sees Revision in Market Evaluation Amidst Challenging Fundamentals

2025-12-01 10:09:27

Ind-Swift Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment highlights the evolving challenges the company faces amid a complex operating environment and fluctuating market sentiment.

Why is Ind-Swift Labs. falling/rising?

2025-11-26 01:02:09

Recent Price Performance and Market Comparison

Ind-Swift Laboratories has experienced a consistent decline over recent trading sessions, with the stock falling for two consecutive days and registering a cumulative loss of 6.5% during this period. The intraday low touched ₹93.5, marking a 2.35% drop from previous levels. This underperformance is further highlighted by the stock’s returns relative to the broader market indices. Over the past week, the stock declined by 2.84%, significantly lagging behind the Sensex’s marginal dip of 0.10%. The one-month performance is even more stark, with Ind-Swift Labs falling 7.78% while the Sensex gained 0.45%. Year-to-date figures reveal a 14.18% loss for the stock, contrasting sharply with the Sensex’s 8.25% gain.

Technical indicat...

Ind-Swift Laboratories Q2 FY26: Recovery Momentum Stalls Amid Margin Pressures

2025-11-18 16:41:33

Ind-Swift Laboratories Ltd., the Chandigarh-based active pharmaceutical ingredient (API) manufacturer, reported a consolidated net profit of ₹7.99 crores for Q2 FY26, marking an impressive 1848.78% year-on-year growth from ₹0.41 crores in Q2 FY25. However, the quarter-on-quarter picture reveals concerning trends, with net profit declining 8.89% from ₹8.77 crores in Q1 FY26. The micro-cap company, with a market capitalisation of ₹814.00 crores, has seen its stock price decline 2.91% to ₹96.90 as investors digest the mixed quarterly performance.

Ind-Swift Laboratories Faces Mixed Technical Trends Amid Recent Stock Evaluation Changes

2025-11-18 08:07:16

Ind-Swift Laboratories, a microcap in the Pharmaceuticals and Biotechnology sector, has experienced a stock price decline amid mixed technical indicators. Recent performance shows a notable drop compared to the Sensex, with year-to-date losses contrasting with long-term gains, emphasizing the importance of monitoring market conditions.

Ind-Swift Laboratories Shows Stabilization Amidst Recent Financial Trend Adjustments

2025-11-18 08:00:18

Ind-Swift Laboratories has experienced a flat financial performance for the quarter ending September 2025, with recent evaluations indicating stabilization in its metrics. The stock has shown volatility in trading, and while it has underperformed against the Sensex over the past year, it has outperformed over longer time frames.

How has been the historical performance of Ind-Swift Labs.?

2025-11-17 23:03:16

Answer: The historical performance of Ind-Swift Labs shows significant fluctuations in key financial metrics over the years. Breakdown: Ind-Swift Labs experienced a notable decline in net sales from INR 1,709.15 crore in March 2024 to INR 561.71 crore in March 2025, following a peak of INR 1,207.31 crore in March 2023. The total operating income mirrored this trend, dropping to INR 561.71 crore in March 2025 from INR 1,709.15 crore in the previous year. The company's operating profit (PBDIT) also fell sharply, resulting in a loss of INR 19.39 crore in March 2025, compared to a profit of INR 303.06 crore in March 2024. Despite these challenges, profit before tax remained positive at INR 257.80 crore in March 2025, although it decreased from INR 598.22 crore in March 2024. The profit after tax for March 2025 was INR 250.53 crore, down from INR 539.24 crore the previous year. On the balance sheet, total liabi...

Why is Ind-Swift Labs. falling/rising?

2025-11-17 22:20:08

As of 17-Nov, Ind-Swift Laboratories Ltd's stock price is currently at Rs 99.40, reflecting a decrease of Rs 4.5 or 4.33%. The stock has underperformed its sector by 4.61% today and has experienced a trend reversal after two consecutive days of gains. It reached an intraday low of Rs 99.1, indicating a significant drop of 4.62%. Additionally, the stock's performance over the past week shows a decline of 4.42%, and it has underperformed the benchmark Sensex, which has gained 1.69% during the same period. The delivery volume has also decreased by 14.86% compared to the five-day average, suggesting a decline in investor participation. Broader Market Context: In the context of the broader market, Ind-Swift Laboratories Ltd's year-to-date performance shows a decline of 9.39%, while the Sensex has risen by 8.72% during the same timeframe. This stark contrast highlights the stock's struggles compared to the overa...

Is Ind-Swift Labs. technically bullish or bearish?

2025-11-17 08:05:52

As of 14 November 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum. However, the weekly and monthly MACD and KST readings are mildly bearish, which suggests some caution. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish on the monthly. Dow Theory indicates a mildly bullish stance on both weekly and monthly timeframes. Overall, the mixed signals from different indicators suggest a cautious bullish outlook....

Ind-Swift Laboratories Shows Mixed Technical Trends Amid Market Fluctuations

2025-11-17 08:00:58

Ind-Swift Laboratories, a microcap in the Pharmaceuticals and Biotechnology sector, has seen its stock price rise slightly. The company has experienced fluctuations over the past year, with notable returns compared to the Sensex. Its performance over three years has significantly outpaced the index, indicating resilience in a competitive market.

View All News

Announcement

Ind-Swift Laboratories Limited - Updates

09-Dec-2019 | Source : NSE

Ind-Swift Laboratories Limited has informed the Exchange regarding 'Prior Intimation under Regulation 50 (1) and 60 (2) of SEBI (Listing Obligations and Disclosure requirements), Regulations, 2015 of Record Date and redemption/Payment of Interest Date'.

Updates

16-Sep-2019 | Source : NSE

Ind-Swift Laboratories Limited has informed the Exchange regarding 'Prior Intimation under Regulations 50(1) and 60(2) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 of Record date and payment of Interest Date'.

Updates

09-Sep-2019 | Source : NSE

Ind-Swift Laboratories Limited has informed the Exchange regarding 'Intimation regarding Publication of Notice of 24th AnnualGeneral Meeting of the Company in the Newspaper'.